Policosanol: Results of a postmarketing surveillance study of 27,879 patients

Current Therapeutic Research - Clinical and Experimental

Volumn 59, Issue 10, 1998, Pages 717-722

  Fernández, Lilia ^a   Más, Rosa ^a   Illnait, Jose ^a   Fernández, Julio César ^a  

^a NATL CENTER FOR SCIENTIFIC RESEARCH   (Cuba)

Author keywords

Cholesterol lowering drugs; Policosanol; Postmarketing surveillance

Indexed keywords

POLICOSANOL;

ADULT; ARTICLE; BULIMIA; CUBA; DOSE RESPONSE; DRUG EFFICACY; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; FEMALE; HUMAN; INCIDENCE; INSOMNIA; MAJOR CLINICAL STUDY; MALE; POLYURIA; PRESCRIPTION; PRIORITY JOURNAL; WEIGHT REDUCTION;

EID: 0031729810     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0011-393X(98)85030-3     Document Type: Article

References (37)

1. Ferner RB. Newly licensed drugs. BMJ. 1996;313:1157-1158.
2. Joint Committee of Association of the British Pharmaceutical Industry, British Medical Association, the Committee of Safety of Medicines, and the Royal College of General Practitioners. Guidelines on postmarketing surveillance. BMJ. 1988;296:399-400.
3. Venulet J. Potential role of postmarketing research. Drugs Exp Clin Res. 1987;13:673-683.
4. Rawlins MD. Postmarketing surveillance of adverse reactions to drugs. BMJ. 1984;288: 879-880.
5. Menéndez R, Amor M, González RM, et al. Effect of policosanol on the hepatic cholesterol biosynthesis of normocholesterolemic rats. Biol Res. 1996;29:253-257.
6. Menéndez R, Fernández I, del Rio A, et al. Policosanol inhibits cholesterol biosynthesis and enhances LDL processing in cultured human fibroblasts. Biol Res. 1994;27:199-203.
7. Menéndez R, Arruzazabala ML, Más R, et al. Cholesterol-lowering effect of policosanol on rabbits with hypercholesterolemia induced by a wheat starch-casein diet. Br J Nutr. 1997;77:923-932.
8. Arruzazabala ML, Carbajal D, Más R, et al. Cholesterol-lowering effects of policosanol in rabbits. Biol Res. 1994;27:205-208.
9. Rodríguez C, Mesa R, Más R, et al. Estudio del efecto sobre lípidos y lipoproteínas séricos y de la tolerancia al tratamiento oral con dosis crecientes de policosanol en monos Macaca arctoides. Arch Venezol Farmacol Terap. 1992;11:74-79.
10. Rodríguez C, Mesa R, Más R, et al. Study of policosanol oral chronic toxicity in male monkeys (Macaca arctoides). Food Chem Toxicol. 1994;32:565-575.
11. Mesa AR, Más R, Noa M, et al. Toxicity of policosanol in beagle dogs: One year study. Toxicol Lett. 1994;73:81-90.
12. Castaño G, Zardoya R, Illnait J, et al. Efectos del tratamiento con ateromixol (PPG) (5 mg) en pacientes con hiperlipoproteinemia tipo II. PCM. 1991;5:21-28.
13. Pons P, Más R, Illnait J, et al. Efficacy and safety of policosanol in patients with primary hypercholesterolemia. Curr Ther Res. 1992;52:507-513.
14. Soltero I, Fuenmayor I, Colmenares J. Estudio comparativo doble ciego de la eficacia y tolerancia del policosanol vs bezafibrato en pacientes con hiperlipidemias tipo II. Arch Venezol Farmacol Terap. 1993;12:71-76.
15. Pons P, Rodríguez M, Robaina C, et al. Effects of successive dose increases of policosanol on the lipid profile of patients with type II hypercholesterolemia and tolerability to treatment. J Clin Pharmacol Res. 1994;14:27-33.
16. Aneiros E, Más R, Calderón B, et al. Effect of policosanol in lowering cholesterol levels in patients with type II hypercholesterolemia. Curr Ther Res. 1995;56:176-182.
17. Castaño G, Más R, Nodarse M, et al. One-year study of the efficacy and safety of policosanol (5 mg twice daily) in the treatment of type II hypercholesterolemia. Curr Ther Res. 1995;56:296-304.
18. Castaño G, Canetti M, Morera M, et al. Efficacy and tolerability of policosanol in elderly patients with type II hypercholesterolemia: A 12 month study. Curr Ther Res. 1995;56: 819-828.
19. Canetti M, Morera M, Illnait J, et al. One year study on the effect of policosanol (5 mg-twice-a-day) on lipid profile in patients with type II hypercholesterolemia. Adv Ther. 1995;12:245-254.
20. Canetti M, Morera M, Illnait J, et al. A two year study on the efficacy and tolerability of policosanol in patients with type II hypercholesterolemia. Int J Clin Pharmacol Res. 1995;15;159-165.
21. Zardoya R, Tula L, Castaño G, et al. Effects of policosanol on hypercholesterolemic patients with disturbances on serum biochemical indicators of hepatic function. Curr Ther Res. 1996;57:568-577.
22. Castaño G, Tula L, Canetti M, et al. Effects of policosanol in hypertensive patients with type II hypercholesterolemia. Curr Ther Res. 1996;57:691-699.
23. Campilongo R, Sandini P, Feldman R, et al. Eficacia, seguridad y tolerabilidad del policosanol en pacientes argentinos con hipercolesterolemia tipo II. Estudio abierto. Prensa Med Argent. 1996;83:665-672.
24. Pons P, Illnait J, Más R, et al. A comparative study of policosanol versus probucol in patients with hypercholesterolemia. Curr Ther Res. 1997;58:26-35.
25. Castaño G, Más R, Fernández JC, Illnait J. Comparative effects of two once-daily regimens of policosanol in patients with type II hypercholesterolemia. Curr Ther Res. 1997; 58:154-162.
26. Canetti M, Morera MS, Más R, et al. Effects of policosanol on primary hypercholesterolemia: A 3-year open follow-up. Curr Ther Res. 1997;58:868-875.
27. Benítez M, Romero C, Más R, et al. A comparative study of policosanol versus simvastatin in patients with type II hypercholesterolemia. Curr Ther Res. 1997;58:859-867.
28. Ortensi G, Gladstein H, Valli H, Tesone PA. A comparative study of policosanol versus simvastatin in elderly patients with hypercholesterolemia. Curr Ther Res. 1997;58:390-401.
29. Torres O, Agramonte AJ, Illnait J, et al. Treatment of hypercholesterolemia in NIDDM with policosanol. Diabetes Care. 1995;18:393-397.
30. Crespo N, Alvarez R, Más R, et al. Effect of policosanol on patients with non-insulin-dependent diabetes mellitus (NIDDM) and hypercholesterolemia. Curr Ther Res. 1997; 58:44-51.
31. Arruzazabala ML, Carbajal D, Más R, García M. Effectos del Ateromixol (PPG) sobre la agregación plaquetaria. Rev CIENC Biol. 1991;22:72-73.
32. Arruzazabala ML, Carbajal D, Más R, et al. Effects of policosanol on platelet aggregation in rats. Thromb Res. 1992;69:321-327.
33. Valdés S, Arruzazabala ML, Carbajal D, et al. Effect of policosanol on platelet aggregation in healthy volunteers. Int J Clin Pharmacol Res. 1996; 14:67-72.
34. Arruzazabala ML, Valdés S, Más R, et al. Effect of policosanol successive dose increase on platelet aggregation in healthy volunteers. Pharmacol Res. 1996;34:181-185.
35. Scazziota A, Altman R. Efecto del policosanol sobre la función de las plaquetas en voluntarios sanos. Rev Iberoamer Trombosis Hemostasia. 1996;9:58-62.
36. Arruzazabala ML, Valdés S, Más R, et al. Comparative study of policosanol, aspirin and the combination of policosanol-aspirin on platelet aggregation in healthy volunteers. Pharmacol Res. In press.
37. Mölgaard J, Lundh BJ, Von Schenck H, et al. Long-term efficacy and safety of simvastatin alone and in combination therapy in treatment of hypercholesterolemia. Atherosclerosis. 1991;91(Suppl):S21-S28.